semaglutide death rate Cardiovascular outcomes of and tirzepatide for patients with type 2 diabetes in clinical practice Cardiovascular benefits of semaglutide: a

TD: Tardive Dyskinesia for total (+) active metabolites for tetrabenazine & deutetrabenazine Schneider et al (2021) Adapted from Diana (2007), Schneider et al (2021) & Cheung & Parmar (2022) References: Aminoff MJ (2021): Pharmacologic Management of Parkinsonism & Other Movement Disorders Chapter 28

[DOI] [PubMed] [Google Scholar] 117.Bays H.E., Burridge K., Richards J., Fitch A

[PubMed] [Google Scholar] Su D, May JM, Koury MJ, Asard H

10.1073/pnas.86.23.9574 80 LismanJ

Having practiced across traditional clinics, hospital systems, and innovative telehealth platforms, he brings a collaborative, evidence-based approach to clinical oversight